About BioLargo

BioLargo, Inc. (BioLargo) invents, develops, and commercializes platform technologies to solve challenging environmental problems like polyfluoroalkyl substances (PFAS) contamination, advanced water and wastewater treatment, industrial odor control, air quality control, infection control, and myriad environmental remediation challenges. Having conducted continual and extensive research and development, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. With a keen emphasis on partnerships with academic, government, and commercial organizations and associations, BioLargo has proven itself by executing on challenging environmental engineering projects, demonstrating its powerful technologies through pilots, trials, and early commercial adoption, publishing high-impact academic and industry publications, and winning over 90 grants. The company monetizes its innovations through direct sales and recurring service contracts, as well as through channel partnerships, meaning licensing agreements, exclusive and non-exclusive distribution agreements, brand development partnerships, sale referral partnerships, strategic joint venture formation, and/or the sale of the IP. Segments The company operates through four segments: ONM Environmental; Clyra Medical Technologies (Clyra Medical); BLEST; and BioLargo Water (Water). ONM Environmental: This segment manufactures and sells its rW and services (located in Westminster, California). Clyra Medical: This segment develops and sells medical products based on the company's technologies. BLEST: This segment provides professional engineering services on a time and materials basis for outside clients and supports the company's internal operations as needed (located in Oak Ridge, Tennessee). Water: This segment focuses on commercializing the AOS technology (located in Edmonton, Alberta Canada). Strategy The company's business strategy is straightforward: it invents or acquires technologies that have the potential to be disruptive in large commercial markets; it develops and validates these technologies to advance and promote their commercial success as it leverages its considerable scientific, engineering, and entrepreneurial talent; and it then monetizes these technical assets through a variety of business structures that may include licensure, joint venture, sale, spin off, or by deploying direct to market strategies. ONM Environmental - Industrial Odor and VOC Solutions ONM Environmental, Inc. is BioLargo's subsidiary that delivers robust and comprehensive products and services to control and mitigate odor and volatile organic compounds (VOCs) emitted from a variety of industrial activities, including landfills and other waste handling facilities. Its flagship product, CupriDyne Clean, reduces and eliminates tough odors and VOCs in various industrial settings. CupriDyne Clean is delivered through misting systems, sprayers, water trucks and similar water delivery systems designed, manufactured and installed by ONM. In response to customer demand for expanded services, ONM Environmental holds General, Electrical, Plumbing and Low Voltage contractor licenses issued by the California Contractors State License Board, and offers a menu of services to landfills, transfer stations, wastewater treatment facilities, as well as facilities in non-waste related industries. These services include engineering design, construction, installation, ongoing maintenance and on-site support services to assist the company's clients in the implementation and continued use of the various systems that deliver its liquid products in the field (such as misting systems). In addition to growing its revenues organically through the sale of odor and VOC control chemistry and air quality control systems to its primary market segment (municipal solid waste handling in California), ONM Environmental aims to accelerate its growth through development of new sales and distribution channels. Some of these, including the company's partnership with Ikigai Marketing Works, LLC. Consumer Packaged and Private-Label Products The company sells pet odor-control products under the brand Pooph to Ikigai Marketing Works, LLC (Ikigai). In late 2022, Ikigai launched the Pooph product in a limited number of Walmart retail stores, to Walmart stores nationwide in the second quarter (year ended December 31, 2022) of 2023. South Korean Joint Venture The company has a Joint Venture Framework Agreement with a leading wastewater treatment solution provider based in South Korea (BKT Co. Ltd., BKT), to create a South Korean entity that would manufacture odor and VOC control products based on its CupriDyne Clean products. The company owns 40% of the joint venture. Full Service Environmental Engineering The company's subsidiary BioLargo Engineering, Science & Technologies, LLC (BLEST) offers full service environmental engineering to third parties and provides engineering support services to its internal teams to accelerate the commercialization of its technologies. BLEST focuses its efforts in three areas, such as providing engineering services to third-party clients; supporting internal product development and business units' services to customers (e.g., the AOS); and advancing their own technical innovations, such as the Aqueous Electrostatic Concentrator (AEC) PFAS treatment technology and the battery energy storage system, which is recently added to the portfolio. In association with Garratt-Callahan, a national industrial water treatment company, BLEST developed a minimal liquid discharge (MLD) wastewater treatment system based on Garratt-Callahan's patented technology that is able to reduce industrial wastewater discharge and therefore reduce wastewater discharge fees for customers. In the second quarter of 2022, BLEST was contracted by Ultra Safe Nuclear to assist in producing the first prototype fuel production systems for their revolutionary new nuclear reactor called the Micro Modular Reactor (MMR). Waste-to-Energy Conversion Plant Project In April 2022, the company's engineering subsidiary was hired by a Southern California based sustainable energy services company to conduct a comprehensive project plan (i.e., feasibility study) for a waste-to-energy (WTE) conversion plant in South America - one of multiple projects in planning stages by it. The company's engineers completed the initial feasibility study and have delivered a proposal for the next phase of the project (front end engineering design, aka FEED). The client has also requested feasibility studies and a FEED proposal for WTE plants in Asia. BioLargo Water and the Advanced Oxidation System - AOS BioLargo Water is the company's wholly owned subsidiary located in Edmonton, Alberta, Canada, that developed and is attempting to commercialize its Advanced Oxidation water treatment system (AOS). The AOS is the company's patented water treatment device that generates highly oxidative and energetic species of iodine and other molecules, which allow it to rapidly and effectively eliminate pathogenic organisms and organic contaminants as water passes through the device. The company's proof-of-concept studies and on-site pilot projects have generated results that project the AOS will be more cost- and energy-efficient than commonly used advanced water treatment technologies, such as UV, electro-chlorination, and ozonation. Furthermore, the company's technology has been proven capable of removing hard-to-treat organic micropollutants, such as pharmaceuticals from water more quickly and energy-efficiently than other technologies. Together, these characteristics make the AOS an economical and versatile tool to enable wastewater treatment and reuse in the face of emerging water contaminants and increasing regulatory scrutiny on industrial wastewater discharge. Municipal Wastewater Treatment Pilot - Montreal The company's commercial-scale AOS demonstration pilot (run in partnership with acclaimed water experts at the Centre des Technologies de L'Eau) at a municipal wastewater treatment plant near Montreal, Quebec, is ongoing and providing important data that shows the AOS is removing five target pharmaceuticals from the wastewater faster and using less electricity than the ultraviolet disinfections system used in the facility. Notably, the pilot project also showed that the AOS was able to also remove total coliforms (bacteria) from the municipal wastewater more effectively than the UV disinfection system in use at the facility. In January 2022, BioLargo Water was awarded a grant from the government of Canada's Natural Sciences and Engineering Research Council (NSERC) that allowed for the extension of the pilot project to allow for use of a new, higher flow-rate AOS system, as well as the installation of an AEC system at the pilot to assess its removal of PFAS chemicals from the municipality's wastewater, which was completed successfully. Clyra Medical Technologies Clyra Medical Technologies, Inc. (Clyra) is the company's partially owned subsidiary creating medical products based on its technology. It is launching a product to be used by surgeons generally, with a first target market aimed toward orthopedic surgeons for use as a wound irrigation solution and to help manage patient care and outcomes. Clyra has secured its first two hospital customers for the product, established a robust quality control system for FDA compliance, recruited a national director of sales, and is negotiating with three separate channel partners to form a commercial alliance. Its other product designs are on hold until such time as it is able to secure the capital and resources to complete any final development and support additional inventory, technical support and sales for these products. BioLargo Energy Technologies, Inc. BioLargo acquired a proprietary sodium-sulfur battery technology and has formed and secured initial capital for a subsidiary - BioLargo Energy Technologies, Inc. (BETI) - designed to address the ongoing shift toward renewable energy production and the growth in global electricity demand, and the consequent drastic expansion in energy storage capacity in the U.S. and world-wide that will be needed to accommodate increased demand and the intermittent nature of renewable energy sources like wind and solar. Intellectual Property The company has 25 patents issued, including 19 in the United States, and multiple pending. The company regards its intellectual property as critical to its ultimate success. U.S. Patents U.S. Patent 11,565,947 issued January 31, 2023, related to the mitigation of microbe buildup within a potable water supply system, incorporating the use of certain BioLargo technologies. U.S. Patent 11,457,632, issued October 5, 2022, relating to liquid antimicrobial disinfectant compositions for the treatment of coronaviruses and SARS-CoV-2 on skin and surfaces, which have extended antimicrobial and antiviral activity for more than 24 hours, are suitable for personal, clinical and surgical use, and are safe to skin, mucous membranes and wounds. U.S. Patent 10,654,731, issued on May 19, 2020, 10,238,990, issued on March 26, 2019, and 10,051,866, issued on August 21, 2018, which protect the company's AOS system. U.S. Patent 10,046,078, issued on August 14, 2018, relating to the misting systems that eliminate odors in waste transfer stations, landfills, and other waste handling facilities. U.S. Patent 9,883,653 issued on February 6, 2018, which encompasses a litter composition used in the absorption of animal wastes. US Patent 9,414,601 granted August 16, 2016, relating to the use of an article for application to a surface to provide antimicrobial and/or anti-odor activity. At least one of the reagents is coated with a water-soluble, water dispersible or water-penetrable covering that prevents ambient conditions of 50% relative humidity at 25ºC from causing more than 10% of the total reagents exposed to the ambient conditions from reacting in a twenty-four hour period. U.S. Patent 8,846,067, issued on September 30, 2014, which encompasses a method of treating a wound or burn on tissue to reduce microbe growth about a wound comprising applying an antimicrobial composition to the wound or burn on tissue using a proprietary stable iodine gel or liquid. This patent covers the company's technology as used in products being developed by its subsidiary, Clyra Medical Technologies. U.S. Patent 8,757,253, issued on June 24, 2014, relating to the moderation of oil extraction waste environments. U.S. Patent 8,734,559, issued on May 27, 2014, relating to the moderation of animal waste environments. U.S. Patent 8,679,515 issued on March 25, 2014, titled Activated Carbon Associated with Alkaline or Alkali Iodide, which provides protection for the company's BioLargo AOS filter. U.S. Patent 8,642,057, issued on February 4, 2014, titled Antimicrobial and Antiodor Solutions and Delivery Systems, relating to the company's liquid antimicrobial solutions, including its gels, sprays and liquids imbedded into wipes and other substrates. U.S. Patent 8,574,610, issued on November 5, 2013, relating to flowable powder compositions, including the company's cat litter additive. U.S. Patent 8,257,749, issued on September 4, 2012, relating to the use of the company's technology as protection of against antimicrobial activity in environments that need to be protected or cleansed of microbial or chemical material. These environments include closed and open environments and absorbent sheet materials that exhibit stability until activated by aqueous environments. The field also includes novel particle technology, coating technology or micro-encapsulation technology to control the stability of chemicals that may be used to kill or inhibit the growth of microbes to water vapor or humidity for such applications. U.S. Patent 8,226,964, issued on July 24, 2012, relating to use of the company's technology as a treatment of residue, deposits or coatings within large liquid carrying structures, such as pipes, drains, ducts, conduits, run-offs, tunnels and the like, using iodine, delivered in a variety of physical forms and methods, including using its action to physically disrupt coatings. The iodine's disruptive activity may be combined with other physical removal systems such as pigging, scraping, tunneling, etching or grooving systems or the like. U.S. Patent 8,021,610, issued on September 20, 2011, titled System providing antimicrobial activity to an environment, relating to the reduction of microbial content in a land mass. Related to this patent are patents held in Canada and the European Union. U.S. Patent 7,943,158, issued on May 17, 2011, titled Absorbent systems providing antimicrobial activity, relating to the reduction of microbial content by providing molecular iodine to stabilized reagents. U.S. Patent 7,867,510, issued on January 11, 2011, titled Material having antimicrobial activity when wet, relating to articles for delivering stable iodine-generating compositions. Pending Patent Applications Subject to adequate financing, the company intends to continue to expand and enhance its suite of intellectual property through ongoing focus on product development, new intellectual property development and patent applications, and further third-party testing and validations for specific areas of focus for commercial exploitation. The company anticipates that additional patent applications will be filed during the next 12 months with the USPTO and the international Patent Cooperation Treaty PCT, although it is uncertain of the cost of such patent filings, which will depend upon the number of such applications prepared and filed. Research and Development For the year ended December 31, 2022, the company's research and development expenses were $1,319,000. History BioLargo, Inc. was founded under the laws of the state of Delaware in 1991. The company was incorporated in 1991.